Nanohale AG (FYB) | WebDisclosure

Switch to English

8302	Sociétés
115129	Mots-clés
55450	Articles
62533	Communiqués

Accueil
Sociétés
Nanohale AG

BRÈVE

publiée le 11/03/2024 à 07:35, il y a 8 mois 10 jours

FYB201/Ranibizumab obtient l'approbation et son lancement est prévu dans la région MENA

Formycon AG MS Pharma Ranibizumab Région MENA Rétinopathies Diabétiques
COMMUNIQUÉ DE PRESSE

publié le 11/03/2024 à 07:30, il y a 8 mois 10 jours

FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region
Formycon AG and MS Pharma announce the approval and market launch of FYB201/Ranibizumab in the MENA region, with plans for commercialization in Saudi Arabia and other countries in 2024

MENA Region Formycon AG MS Pharma FYB201/Ranibizumab Biosimilar
COMMUNIQUÉ DE PRESSE

publié le 29/01/2024 à 22:15, il y a 9 mois 23 jours

Gedeon Richter becomes strategic investor of Formycon via equity investment
Formycon AG announces strategic investment from Gedeon Richter, leading to a 9.08% equity takeover via cash capital increase of EUR 82.84 million. The investment will ensure high development pace and operational progress

Pharmaceutical Industry Formycon AG Gedeon Richter Equity Investment Biosimilars
COMMUNIQUÉ DE PRESSE

publié le 29/01/2024 à 22:10, il y a 9 mois 23 jours

EQS-Adhoc: Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor
Formycon AG resolves on EUR 82.84 million cash capital increase by issuing 1,603,877 new shares, all subscribed by Gedeon Richter as strategic investor. Proceeds for biosimilar pipeline development. New shares to be traded on Frankfurt Stock Exchange

Frankfurt Stock Exchange Formycon AG Cash Capital Increase Gedeon Richter Biosimilar Pipeline
COMMUNIQUÉ DE PRESSE

publié le 10/11/2023 à 06:30, il y a 1 année

Formycon hosts conference call on nine-month figures 2023 and presents at further investor conferences
COMMUNIQUÉ DE PRESSE

publié le 10/10/2023 à 07:30, il y a 1 année 1 mois

Formycon Ranibizumab Biosimilar FYB201/CIMERLI®1 achieved 25% market share2 in the United States
COMMUNIQUÉ DE PRESSE

publié le 29/09/2023 à 07:30, il y a 1 année 1 mois

Formycon and Fresenius Kabi announce European Medicines Agency Submission Acceptance of the Marketing Authorization Application for FYB202, an Ustekinumab Biosimilar Candidate
COMMUNIQUÉ DE PRESSE

publié le 30/08/2023 à 07:30, il y a 1 année 2 mois

Formycon reports successful first half of 2023
COMMUNIQUÉ DE PRESSE

publié le 29/08/2023 à 07:30, il y a 1 année 2 mois

Formycon announces File Acceptance for FYB203, a biosimilar candidate to Eylea®1 (aflibercept), by the U.S. Food and Drug Administration (FDA)
COMMUNIQUÉ DE PRESSE

publié le 23/08/2023 à 07:30, il y a 1 année 2 mois

Formycon hosts conference call on financial and earnings position for H1 2023

Les Echos

Publié le 21/11/2024 à 06:58, il y a 20 heures 29 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 20 heures 29 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 20 heures 29 minutes

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 1 jour 7 heures

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 1 jour 8 heures

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 22/11/2024 à 00:00, il y a 3 heures 27 minutes

Gratomic Announces Company and Operational Update
Publié le 21/11/2024 à 22:05, il y a 5 heures 22 minutes

Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Publié le 21/11/2024 à 21:50, il y a 5 heures 37 minutes

Seventy Ninth Resources Announces Successful First Reconnaissance at McKellar Copper-Zinc and Enable Gold Projects
Publié le 21/11/2024 à 20:15, il y a 7 heures 12 minutes

Woodland Park Zoo Awarded Transformative Grant to Advance Empathy for Animals
Publié le 21/11/2024 à 20:10, il y a 7 heures 17 minutes

For Us TV Productions, a Portfolio Company of Belle Bonica Luxe Corp., Invites BIPOC Filmmakers and Producers to Join Its Inclusive Streaming Platform

Voir tout ACCESSWIRE

EQS Group

Publié le 21/11/2024 à 19:01, il y a 8 heures 26 minutes

Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 21/11/2024 à 18:36, il y a 8 heures 51 minutes

Original-Research: Beaconsmind AG (von First Berlin Equity Research GmbH): BUY
Publié le 21/11/2024 à 17:58, il y a 9 heures 29 minutes

Funding Circle Plc: POS-Transaction in Own Shares
Publié le 21/11/2024 à 17:51, il y a 9 heures 35 minutes

LIGHTON announces highly successful IPO on Euronext Growth Paris.
Publié le 21/11/2024 à 17:51, il y a 9 heures 35 minutes

LIGHTON annonce le vif succès de son introduction en Bourse sur Euronext Growth Paris.